SPRB Stock Forecast & Price Target

Spruce Biosciences is positioned favorably because TA-ERT addresses MPS IIIB, a severe rare endocrine disorder with no approved therapies, and the company’s clinical package is being viewed as increasingly credible for accelerated approval based on biomarker reduction alongside stabilization in cognition and motor function. The investment case is strengthened by supportive regulatory precedent, FDA commentary favoring flexibility, and the planned 4Q26 BLA submission, while the company’s ~$60M EV or ~$130M market cap appears disconnected from the potential value of a Priority Review Voucher alone, estimated at ~$150M to $200M, before any commercial sales. Its fundamentals are further supported by $96M in cash, runway into 2H27, steady CMC progress, initiation of the TrAnsform confirmatory study in 4Q26, and physician checks indicating peak sales exceeding $300M.

Spruce Biosciences is a development-stage biotech with a narrow pipeline, leaving its valuation highly dependent on TA-ERT for MPS IIIB and a preclinical SPR202 program, while its other efforts remain early-stage. The investment case is weakened by major regulatory uncertainty because no approved MPS IIIB therapies exist, and approval would rely on Phase 2 biomarker normalization rather than established clinical endpoints. Financially, 2Q26 OpEx of $17M exceeded expectations, the company posted a net loss of $16M, and continued losses plus likely capital raises create dilution risk before any commercial revenue is visible.